Arvinas, Inc. Profile Avatar - Palmy Investing

Arvinas, Inc.

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera…

Biotechnology
US, New Haven [HQ]

Document Reader

Click To Read:

DEF 14-A Proxies

Not a single DEF 14-A proxy doc.

10-K Filings

Not a single 10-K doc.

10-Q Filings

Not a single 10-Q doc.

LDA 1/2 Filings [Lobbying]

Not a single LDA doc.

End of ARVN's Analysis
CIK: 1655759 CUSIP: 04335A105 ISIN: US04335A1051 LEI: - UEI: -
Secondary Listings
ARVN has no secondary listings inside our databases.